Barton Ford Haynes, MD

Professor of Medicine
Frederic M. Hanes Distinguished Professor of Medicine
Director of the Human Vaccine Institute in the Department of Medicine
Research Professor of Global Health
Professor of Immunology
Member of the Duke Cancer Institute
Member of the Duke Human Vaccine Institute
Campus mail 106 Research Drive, MSRBII 4090, Durham, NC 27710
Phone (919) 684-5384
Email address hayne002@mc.duke.edu

The Haynes lab is studying host innate and adaptive immune responses to the human immunodeficiency virus (HIV), tuberculosis (TB), and influenza in order to find the enabling technology to make preventive vaccines against these three major infectious diseases.

Mucosal Immune Responses in Acute HIV Infection

The Haynes lab is working to determine why broadly neutralizing antibodies are rarely made in acute HIV infection (AHI), currently a major obstacle in the development of an HIV vaccine. The lab has developed a novel approach to define the B cell repertories in AHI in order to find neutralizing antibodies against the virus. This approach uses linear Immunoglobulin (Ig) heavy and light chain gene expression cassettes to express Ig V(H) and V(L) genes isolated from sorted single B cells as IgG1 antibody without a cloning step. This strategy was used to characterize the Ig repertoire of plasma cells/plasmablasts in AHI and to produce recombinant influenza mAbs from sorted single human plasmablasts after influenza vaccination.

The lab is also studying the earliest effect HIV-1 has on B cells. Analyzing blood and gut-associated lymphoid tissues (GALT) during acute HIV infection, they have found that as early as 17 days after transmission HIV-1 induces B cell class switching and 47 days after transmission, HIV-1 causes considerable damage to GALT germinal centers. They found that in AHI, GALT memory B cells induce polyclonal B cell activation due to the presence of HIV-1-specific, influenza-specific, and autoreactive antibodies. The team concluded from this study that early induction of polyclonal B cell differentiation, along with follicular damage and germinal center loss, may explain why HIV-1 induced antibody responses decline rapidly during acute HIV infection and why plasma antibody responses are delayed.

The lab is also looking at ways of generating long-lived memory B cell responses to HIV infection, another major hurdle in the development of a successful HIV-1 vaccine. The lab has found that in HIV-1 gp120 envelope vaccination and chronic HIV-1 infection, HIV-1 envelope induces predominantly short-lived memory B cell-dependent plasma antibodies.

Immunogen Design

To overcome the high level of genetic diversity in HIV-1 envelope genes, the Haynes lab is developing strategies to induce antibodies that cross-react with multiple strains of HIV. The lab has designed immunogens based on transmitted founder Envs and mosaic consensus Envs in collaboration with Dr. Bette Korber at Los Alamos National Laboratory. These immunogens are designed to induce antibodies that cross-react with a multiple subtype Env glycoproteins. The goal is to determine if cross-reactive mAbs to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced. The team recently characterized a panel of ten mAbs that reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env protein. Two of the mAbs cross-reacted with all tested Env proteins, including SIVcpzUS Env and bound Env proteins with high affinity.

Mucosal Immune Responses in TB and Influenza

The Haynes lab is helping to develop novel approaches to TB vaccine development. The current therapeutic vaccine for TB, called BCG, may prevent complications from TB in children, but offers little protection against infection and disease in adults. The lab is focused on using live attenuated Mycobacterium tuberculosis mutants as vaccine candidates and is currently evaluating this approach in non-human primate studies. As part of the DHVI Influenza program, they are studying the B cell response to influenza in order to generate a “universal” flu vaccine. They are currently trying to express more highly conserved influenza antigens in recombinant vesicular stomatitis virus (rVSV) vectors in order to elicit robust T cell and antibody responses to those antigens.

Education and Training

  • M.D., Baylor University, 1973

Publications

Alam, S Munir, Kenneth Cronin, Robert Parks, Kara Anasti, Haitao Ding, Eden P. Go, Heather Desaire, et al. “Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.” J Virol 94, no. 21 (October 14, 2020). https://doi.org/10.1128/JVI.00958-20.

PMID
32817216
Full Text

Laczkó, Dorottya, Michael J. Hogan, Sushila A. Toulmin, Philip Hicks, Katlyn Lederer, Brian T. Gaudette, Diana Castaño, et al. “A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.” Immunity 53, no. 4 (October 13, 2020): 724-732.e7. https://doi.org/10.1016/j.immuni.2020.07.019.

PMID
32783919
Full Text

Tuyishime, Marina, Carolina Garrido, Shalini Jha, Matt Moeser, Dieter Mielke, Celia LaBranche, David Montefiori, et al. “Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.” J Clin Invest 130, no. 10 (October 1, 2020): 5157–70. https://doi.org/10.1172/JCI135557.

PMID
32584790
Full Text

Henderson, Rory, Robert J. Edwards, Katayoun Mansouri, Katarzyna Janowska, Victoria Stalls, Sophie M. C. Gobeil, Megan Kopp, et al. “Controlling the SARS-CoV-2 spike glycoprotein conformation.” Nat Struct Mol Biol 27, no. 10 (October 2020): 925–33. https://doi.org/10.1038/s41594-020-0479-4.

PMID
32699321
Full Text

Edwards, Robert J., Katayoun Mansouri, Victoria Stalls, Kartik Manne, Brian Watts, Rob Parks, Sophie M. C. Gobeil, et al. “Cold sensitivity of the SARS-CoV-2 spike ectodomain.” Biorxiv, July 13, 2020. https://doi.org/10.1101/2020.07.12.199588.

PMID
32699852
Full Text

Tolbert, William D., Verna Van, Rebekah Sherburn, Marina Tuyishime, Fang Yan, Dung N. Nguyen, Sherry Stanfield-Oakley, et al. “Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.” Mbio 11, no. 3 (June 30, 2020). https://doi.org/10.1128/mBio.00208-20.

PMID
32605979
Full Text

Sempowski, Gregory D., Kevin O. Saunders, Priyamvada Acharya, Kevin J. Wiehe, and Barton F. Haynes. “Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.” Cell 181, no. 7 (June 25, 2020): 1458–63. https://doi.org/10.1016/j.cell.2020.05.041.

PMID
32492407
Full Text

Kasturi, Sudhir Pai, Mohammed Ata Ur Rasheed, Colin Havenar-Daughton, Mathew Pham, Traci Legere, Zarpheen Jinnah Sher, Yevgeny Kovalenkov, et al. “3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.” Sci Immunol 5, no. 48 (June 19, 2020). https://doi.org/10.1126/sciimmunol.abb1025.

PMID
32561559
Full Text

Hompe, Eliza D., Jesse F. Mangold, Amit Kumar, Joshua A. Eudailey, Erin McGuire, Barton F. Haynes, M Anthony Moody, et al. “Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials.” Msphere 5, no. 3 (June 3, 2020). https://doi.org/10.1128/mSphere.00254-20.

PMID
32493720
Full Text

Henderson, Rory, Robert J. Edwards, Katayoun Mansouri, Katarzyna Janowska, Victoria Stalls, Sophie Gobeil, Megan Kopp, et al. “Controlling the SARS-CoV-2 Spike Glycoprotein Conformation.” Biorxiv, May 18, 2020. https://doi.org/10.1101/2020.05.18.102087.

PMID
32511343
Full Text

Pages